CATXNYSEPharmaceutical PreparationsFiscal year ends December 31
Perspective Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$2.19+0.02 (+0.92%)
Close on Oct 19, 2026
- Market cap
- $264.23M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
78.2%
89M of 114M shares
Institutional holders
130
24 new, 29 sold out
Net institutional buying
5M
In Q2 2026
Insider trades, 12 months
2 buys · 7 sales
Net sold $1.58M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Lantheus Alpha Therapy, LLC | 8,739,011 | 7.70% | 13D (active) amendment | Sep 21, 2026 |
| Chen Yu | 7,915,567 | 6.90% | 13G (passive) | Feb 3, 2026 |
| BlackRock, Inc. | 7,776,940 | 6.80% | 13G (passive) | Jun 30, 2026 |
| Qatar Investment Authority | 7,073,308 | 6.20% | 13G (passive) | Feb 4, 2026 |
| Israel A. Englander | 6,316,545 | 5.50% | 13G (passive) amendment | Aug 7, 2026 |
| FMR LLC | 6,063,330 | 8.20% | 13G (passive) amendment | Oct 31, 2025 |
| State Street Corporation | 6,051,771 | 5.30% | 13G (passive) | Jun 30, 2026 |
| Avidity Partners Management (GP) LLC | 6,049,999 | 5.30% | 13G (passive) | Feb 20, 2026 |
| Millennium Management LLC | 6,036,999 | 5.30% | 13G (passive) | Jul 13, 2026 |
| Johnson Frances | 16,779,075 | 5.90% | 13G (passive) amendment | Dec 31, 2023 |
| Schultz Michael K | 16,779,075 | 5.90% | 13G (passive) amendment | Dec 31, 2023 |
| Michael Kramarz | 11,939,753 | 9.90% | 13G (passive) | Feb 2, 2026 |
| Lantheus Medical Imaging, Inc. | 11,440,513 | 10.00% | 13D (active) amendment | May 15, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CATX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 9,494,152 | 8.32% | $32.38M | +4,145,591 | 0.00% |
| TCG Crossover Management, LLC | 7,915,567 | 6.93% | $26.99M | – | 0.65% |
| Commodore Capital LP | 6,336,782 | 5.55% | $21.61M | – | 1.29% |
| Avidity Partners Management LP | 6,299,999 | 5.52% | $21.48M | −5,799,999 | 3.44% |
| State Street Corp | 6,051,771 | 5.30% | $20.64M | +2,919,101 | 0.00% |
| Millennium Management LLC | 4,911,855 | 4.30% | $16.75M | +865,215 | 0.01% |
| Nantahala Capital Management, LLC | 4,650,900 | 4.07% | $15.86M | New | 0.26% |
| Vanguard Capital Management LLC | 4,436,572 | 3.89% | $15.13M | +57,616 | 0.00% |
| Affinity Asset Advisors, LLC | 4,214,582 | 3.69% | $14.37M | +1,050,000 | 0.65% |
| Citadel Advisors LLC | 3,805,739 | 3.33% | $12.98M | +239,235 | 0.00% |
| Spruce Street Capital LP | 3,693,931 | 3.24% | $12.60M | +1,066,824 | 2.47% |
| Balyasny Asset Management L.P. | 3,320,224 | 2.91% | $11.32M | +325,764 | 0.01% |
| Geode Capital Management, LLC | 2,458,673 | 2.15% | $8.39M | +691,713 | 0.00% |
| Morgan Stanley | 1,912,550 | 1.68% | $6.52M | −1,070,792 | 0.00% |
| Goldman Sachs Group Inc | 1,733,078 | 1.52% | $5.91M | +491,262 | 0.00% |
| Nicholson Wealth Management Group, LLC | 1,619,993 | 1.42% | $5.52M | +1,000 | 3.25% |
| Two Sigma Investments, LP | 1,556,451 | 1.36% | $5.31M | +552,977 | 0.00% |
| ADAR1 Capital Management, LLC | 1,210,117 | 1.06% | $4.13M | +460,782 | 0.19% |
| Vanguard Portfolio Management LLC | 1,087,767 | 0.95% | $3.71M | +335,734 | 0.00% |
| Dimensional Fund Advisors LP | 1,074,071 | 0.94% | $3.66M | +623,974 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 130 | 89M | 78.2% | 24 / 60 | 26 / 29 | 21M | 16M |
| Q1 2026 | 136 | 85M | 74.1% | 47 / 41 | 28 / 23 | 58M | 6M |
| Q4 2025 | 115 | 36M | 31.8% | 24 / 31 | 36 / 10 | 7M | 14M |
| Q3 2025 | 103 | 43M | 37.6% | 16 / 31 | 30 / 8 | 6M | 5M |
| Q2 2025 | 95 | 42M | 37.0% | 9 / 38 | 22 / 24 | 7M | 9M |
| Q1 2025 | 110 | 44M | 38.7% | 13 / 34 | 38 / 36 | 5M | 7M |
| Q4 2024 | 134 | 47M | 41.3% | 36 / 48 | 31 / 24 | 15M | 16M |
| Q3 2024 | 126 | 49M | 43.0% | 43 / 47 | 22 / 19 | 19M | 5M |
| Q2 2024 | 103 | 39M | 33.8% | 103 / 0 | 0 / 0 | 39M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of CATX | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 4,036,281 | 3.54% | $13.76M | 0.13% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 3,313,065 | 2.90% | $11.30M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,647,335 | 2.32% | $9.03M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,126,721 | 0.99% | $3.28M | 0.01% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 1,017,864 | 0.89% | $3.47M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 977,879 | 0.86% | $3.33M | 0.02% | Jun 30, 2026 |
| iShares Biotechnology ETF | 636,237 | 0.56% | $2.17M | 0.02% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 445,775 | 0.39% | $1.76M | 0.00% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 405,058 | 0.35% | $1.60M | 0.01% | May 31, 2026 |
| iShares Micro-Cap ETF | 346,808 | 0.30% | $1.18M | 0.08% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 319,770 | 0.28% | $1.26M | 0.01% | May 31, 2026 |
| Vanguard Health Care Index Fund | 288,380 | 0.25% | $1.14M | 0.01% | May 31, 2026 |
| U.S. Small Cap Portfolio | 269,566 | 0.24% | $784.44K | 0.00% | Jul 31, 2026 |
| Select Biotechnology Portfolio | 258,600 | 0.23% | $1.02M | 0.02% | May 31, 2026 |
| Dimensional U.S. Small Cap ETF | 254,330 | 0.22% | $740.10K | 0.00% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Johan M. Spoor | Chief Executive Officer, Director | 87,683 | 0.08% | Mar 4, 2026 |
| Jonathan Robert Hunt | Chief Accounting Officer | 59,800 | 0.05% | Mar 4, 2026 |
| Markus Puhlmann | Chief Medical Officer | 1,375,425 | 1.20% | Mar 4, 2026 |
| Joel Sendek | Chief Financial Officer | – | – | Sep 5, 2025 |
| Juan Graham | Chief Financial Officer | 35,354 | 0.03% | Apr 1, 2025 |
| Maria E. Martinez | Director | – | – | Mar 4, 2026 |
| Lori A. Woods | Director | 188,267 | 0.16% | Mar 4, 2026 |
| Frank Morich | Director | – | – | Mar 4, 2026 |
| Robert F. Williamson III | Director | 118,846 | 0.10% | Mar 4, 2026 |
| Heidi Henson | Director | 25,975 | 0.02% | Mar 4, 2026 |
| Lantheus Holdings, Inc. | 10% owner | 11,521,296 | 10.09% | Sep 8, 2026 |
| Lantheus Alpha Therapy, LLC | 10% owner | 11,273,364 | 9.88% | Sep 8, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Lantheus Alpha Therapy, LLC 10% owner | Sep 4, 2026 | Sale | −167,149 | $3.15 | $526.52K | 11,273,364 |
| Lantheus Alpha Therapy, LLC 10% owner | Sep 3, 2026 | Sale | −80,783 | $3.11 | $251.24K | 11,440,513 |
| Lantheus Holdings, Inc. 10% owner | Sep 2, 2026 | Sale | −42,129 | $3.11 | $131.02K | 11,521,296 |
| Lantheus Alpha Therapy, LLC 10% owner | Sep 1, 2026 | Sale | −35,769 | $3.12 | $111.60K | 11,563,425 |
| Lantheus Holdings, Inc. 10% owner | Sep 1, 2026 | Sale | −35,769 | $3.12 | $111.60K | 11,563,425 |
| Lantheus Alpha Therapy, LLC 10% owner | Aug 31, 2026 | Sale | −78,145 | $3.14 | $245.38K | 11,599,194 |
| Lantheus Holdings, Inc. 10% owner | Aug 31, 2026 | Sale | −78,145 | $3.14 | $245.38K | 11,599,194 |
| Jonathan Robert Hunt Chief Accounting Officer | Nov 13, 2025 | Buy | +11,000 | $2.03 | $22.33K | 59,800 |
| Robert F. Williamson III Director | Nov 12, 2025 | Buy | +9,498 | $2.10 | $19.95K | 9,864 |
| Lori A. Woods Director | Mar 31, 2025 | Buy | +23,475 | $2.13 | $50.00K | 183,460 |
| Robert F. Williamson III Director | Mar 31, 2025 | Buy | +38,145 | $2.14 | $81.63K | 108,982 |
| Juan Graham Chief Financial Officer | Mar 28, 2025 | Buy | +33,333 | $2.25 | $75.00K | 35,354 |
| Robert F. Williamson III Director | Mar 28, 2025 | Buy | +22,192 | $2.27 | $50.38K | 70,837 |
| Johan M. Spoor Chief Executive Officer, Director | Mar 28, 2025 | Buy | +22,026 | $2.24 | $49.34K | 59,383 |
| Johan M. Spoor Chief Executive Officer, Director | Mar 28, 2025 | Buy | +4,650 | $2.21 | $10.28K | 4,650 |
| Heidi Henson Director | Dec 4, 2024 | Buy | +25,975 | $3.85 | $100.00K | 25,975 |
| Johan M. Spoor CEO, Director | Dec 4, 2024 | Buy | +8,000 | $3.77 | $30.16K | 36,257 |
| Jonathan Robert Hunt Chief Financial Officer | Nov 25, 2024 | Buy | +29 | $3.94 | $114 | 36,400 |
| Jonathan Robert Hunt Chief Financial Officer | Nov 25, 2024 | Buy | +400 | $3.55 | $1.42K | 36,371 |
| Jonathan Robert Hunt Chief Financial Officer | Nov 25, 2024 | Buy | +2,400 | $3.60 | $8.64K | 38,800 |
| Jonathan Robert Hunt Chief Financial Officer | Nov 25, 2024 | Buy | +10,000 | $3.88 | $38.80K | 48,800 |
| Robert F. Williamson III Director | Nov 25, 2024 | Buy | +2,619 | $3.67 | $9.61K | 430,058 |
| Robert F. Williamson III Director | Nov 25, 2024 | Buy | +3,647 | $3.62 | $13.20K | 427,439 |
| Johan M. Spoor CEO, Director | Nov 25, 2024 | Buy | +5,400 | $3.80 | $20.52K | 5,400 |
| Johan M. Spoor CEO, Director | Nov 25, 2024 | Buy | +14,500 | $3.78 | $54.81K | 152,072 |
| Johan M. Spoor CEO, Director | Nov 25, 2024 | Buy | +6,600 | $3.80 | $25.08K | 66,600 |
| Jonathan Robert Hunt Chief Financial Officer | Jun 17, 2024 | Buy | +1,800 | $9.82 | $17.68K | 35,971 |
| Lori A. Woods Director | Jun 14, 2024 | Buy | +83 | $10.80 | $896 | 159,985 |
| Lori A. Woods Director | Jun 14, 2024 | Buy | +4,504 | $10.90 | $49.09K | 159,902 |
| Johan M. Spoor CEO, Director | Jun 13, 2024 | Buy | +100,000 | $1.17 | $117.00K | 137,572 |
| Lori A. Woods Director | Jun 3, 2024 | Buy | +34,246 | $1.46 | $50.00K | 1,553,984 |
| Robert F. Williamson III Director | May 31, 2024 | Buy | +55,000 | $1.38 | $75.90K | 423,792 |
| Jonathan Robert Hunt Chief Financial Officer | May 31, 2024 | Buy | +12,000 | $1.40 | $16.80K | 341,716 |
| Jonathan Robert Hunt Chief Financial Officer | May 31, 2024 | Buy | +13,006 | $1.40 | $18.21K | 329,716 |
| Robert F. Williamson III Director | May 29, 2024 | Buy | +18,656 | $1.34 | $25.00K | 368,792 |
| Robert F. Williamson III Director | May 29, 2024 | Buy | +11,375 | $1.32 | $15.02K | 350,136 |
| Mark John Austin VP Finance/Prin Fin&Acct Offic | Apr 23, 2024 | Option exercise | +30,000 | $0.36 | $10.80K | 84,030 |
| Lantheus Alpha Therapy, LLC 10% owner | Mar 6, 2024 | Buy | +60,431,039 | $0.95 | $57.41M | 116,773,394 |
| Robert F. Williamson III Director | Jan 30, 2024 | Buy | +3,500 | $0.70 | $2.45K | 338,761 |
| Robert F. Williamson III Director | Jan 30, 2024 | Buy | +18,579 | $0.71 | $13.19K | 230,134 |
| Robert F. Williamson III Director | Jan 30, 2024 | Buy | +5,127 | $0.71 | $3.64K | 235,261 |
| Robert F. Williamson III Director | Jan 30, 2024 | Buy | +57,121 | $0.71 | $40.56K | 292,382 |
| Robert F. Williamson III Director | Jan 30, 2024 | Buy | +42,879 | $0.72 | $30.87K | 335,261 |
| Robert F. Williamson III Director | Jan 29, 2024 | Buy | +4,031 | $0.64 | $2.58K | 190,320 |
| Robert F. Williamson III Director | Jan 29, 2024 | Buy | +21,235 | $0.64 | $13.59K | 211,555 |
| Robert F. Williamson III Director | Jan 26, 2024 | Buy | +14,850 | $0.61 | $9.06K | 102,776 |
| Robert F. Williamson III Director | Jan 26, 2024 | Buy | +12,250 | $0.61 | $7.47K | 87,926 |
| Robert F. Williamson III Director | Jan 26, 2024 | Buy | +50,000 | $0.54 | $27.00K | 186,289 |
| Robert F. Williamson III Director | Jan 26, 2024 | Buy | +25,000 | $0.55 | $13.75K | 136,289 |
| Robert F. Williamson III Director | Jan 26, 2024 | Buy | +8,513 | $0.59 | $5.02K | 111,289 |
| Robert F. Williamson III Director | Jan 25, 2024 | Buy | +22,134 | $0.49 | $10.85K | 75,676 |
| Markus Puhlmann Chief Medical Officer | Jan 24, 2024 | Buy | +280,000 | $0.50 | $140.00K | 1,375,425 |
| Robert F. Williamson III Director | Jan 24, 2024 | Buy | +29,862 | $0.49 | $14.63K | 53,542 |
| Robert F. Williamson III Director | Dec 21, 2023 | Buy | +3,663 | $0.33 | $1.21K | 3,663 |
| Markus Puhlmann Chief Medical Officer | Dec 19, 2023 | Buy | +400,000 | $0.34 | $136.00K | 1,095,425 |
| Robert F. Williamson III Director | Dec 19, 2023 | Buy | +13,680 | $0.32 | $4.38K | 23,680 |
| Jonathan Robert Hunt Chief Financial Officer | Dec 18, 2023 | Buy | +125,000 | $0.26 | $32.50K | 316,710 |
| Markus Puhlmann Chief Medical Officer | Dec 18, 2023 | Buy | +60,419 | $0.26 | $15.71K | 695,425 |
| Robert F. Williamson III Director | Dec 18, 2023 | Buy | +10,000 | $0.26 | $2.60K | 10,000 |
| Markus Puhlmann Chief Medical Officer | Dec 15, 2023 | Buy | +135,006 | $0.27 | $36.45K | 635,006 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Austin Mark affiliate | Sep 12, 2024 | 2,500 | $39.50K | Sep 12, 2024 | Option Exercise and Sell All |